EcoDrugPlus

Purinergic Receptor P2y12

Ensembl ID : ENSHBUG00000023756
Gene Symbol: P2RY12
1 Cross references
180 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSHBUG00000014498
Gene Symbol: P2RY4
4 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSHBUG00000014662
Gene Symbol: P2RY6
4 Cross references
182 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSHBUG00000004428
Gene Symbol: RAMP1
3 Cross references
184 Possible Orthologues:

Receptor Activity-Modifying Protein 1-Like

Ensembl ID : ENSHBUG00000017748
Gene Symbol: LOC102289492
4 Cross references
191 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSHBUG00000005852
Gene Symbol: RIPK1
3 Cross references
197 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSHBUG00000004664
Gene Symbol: LOC102304206
3 Cross references
206 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSHBUG00000001516
Gene Symbol: RPTOR
3 Cross references
213 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSHBUG00000011869
Gene Symbol: RET
3 Cross references
204 Possible Orthologues:

Retinoic Acid Receptor Rxr-Alpha-A

Ensembl ID : ENSHBUG00000012589
Gene Symbol: LOC102297781
3 Cross references
225 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A-Like

Ensembl ID : ENSHBUG00000018792
Gene Symbol: LOC102294784
3 Cross references
211 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSHBUG00000017952
Gene Symbol: RARB
4 Cross references
393 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).